Arena Pharmaceuticals, Inc. (ARNA)
Stock Price:
$63.27 USD
-1.36 (-2.10%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
3.65B |
| Revenue (ttm) |
4.61M |
| Net Income (ttm) |
-346.31M |
| Shares Out |
57.65M |
| EPS (ttm) |
-6.82 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$63.27 |
| Previous Close |
$64.63 |
| Change ($) |
-1.36 |
| Change (%) |
-2.10% |
| Day's Open |
64.75 |
| Day's Range |
62.70 - 66.22 |
| Day's Volume |
428,934 |
| 52-Week Range |
32.95 - 69.75 |
More Stats
| Market Cap |
3.65B |
| Enterprise Value |
2.52B |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
57.65M |
| Float |
57.56M |
| EPS (basic) |
-6.86 |
| EPS (diluted) |
-6.82 |
| FCF / Share |
-5.48 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.40M |
| Short Ratio |
6.69 |
| Short % of Float |
7.32% |
| Beta |
1.41 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
790.49 |
| PB Ratio |
3.77 |
| Revenue |
4.61M |
| Operating Income |
-365.74M |
| Net Income |
-346.31M |
| Free Cash Flow |
-289.09M |
| Net Cash |
1.12B |
| Net Cash / Share |
19.48 |
| Gross Margin |
12,460.66% |
| Operating Margin |
-7,926.83% |
| Profit Margin |
-7,505.70% |
| FCF Margin |
-6,265.47% |
| ROA |
-17.42% |
| ROE |
-28.34% |
| ROIC |
-36.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (12)
| Buy |
12 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$82.58*
(30.52% upside)
Low
70.0
Current: $63.27
High
95.0
Target: 82.58
*Average 12-month price target from 12 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 806 | 17.97 | 21.34 | 92.16 | 13.40 | 36.97 | 81.39 | 27.59 | 12.72 | 16.61 |
| Revenue Growth | 4387.65% | -15.78% | -76.85% | 587.89% | -63.76% | -54.58% | 195.04% | 116.9% | -23.44% | - |
| Gross Profit | 806 | 17.97 | 21.34 | 92.16 | 13.40 | 29.21 | 75.21 | 23.92 | 4.62 | 9.20 |
| Operating Income | 483 | -145 | -91.97 | -5.26 | -104 | -105 | -22.94 | -57.11 | -82.80 | -96.36 |
| Net Income | 398 | -29.40 | -91.41 | -22.52 | -108 | -60.51 | -19.44 | -85.48 | -109 | -125 |
| Shares Outstanding | 49.78 | 47.04 | 32.99 | 24.31 | 24.07 | 21.97 | 21.81 | 19.65 | 13.92 | 10.96 |
| Earnings Per Share | 7.69 | -0.63 | -2.77 | -0.93 | -4.49 | -2.80 | -0.90 | -4.50 | -8.00 | -11.40 |
| Operating Cash Flow | 569 | -132 | -66.64 | -61.48 | -98.11 | -101 | 72.80 | -44.05 | -78.26 | -52.32 |
| Capital Expenditures | -4.82 | -0.69 | 0.68 | 0.14 | 1.11 | -8.86 | -9.10 | -1.75 | -0.59 | -4.16 |
| Free Cash Flow | 564 | -133 | -65.97 | -61.34 | -97.00 | -110 | 63.70 | -45.79 | -78.84 | -56.48 |
| Cash & Equivalents | 740 | 446 | 247 | 90.71 | 156 | 163 | 222 | 156 | 57.63 | 151 |
| Total Debt | 49.43 | 52.71 | 61.75 | 65.27 | 68.25 | 70.74 | 72.79 | 74.46 | 90.47 | 125 |
| Net Cash / Debt | 690 | 393 | 185 | 25.45 | 87.94 | 92.47 | 149 | 81.63 | -32.84 | 25.76 |
| Assets | 1,174 | 687 | 339 | 169 | 257 | 276 | 340 | 261 | 157 | 266 |
| Liabilities | 103 | 80.65 | 132 | 129 | 203 | 229 | 248 | 163 | 147 | 186 |
| Book Value | 1,071 | 606 | 207 | 39.90 | 53.54 | 47.35 | 91.86 | 98.64 | 10.56 | 80.02 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Arena Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
320 |
| CEO |
Amit Dilip Munshi |
Stock Information
| Ticker Symbol |
ARNA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ARNA |
| IPO Date |
July 28, 2000 |
Description
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.